Related Experiment Video
Updated: Mar 11, 2026

10:56
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
8.6K
Increasing the Detection of Familial Hypercholesterolaemia Using General Practice Electronic Databases
Alistair W Vickery1, Jackie Ryan2, Jing Pang2
1School of Primary, Aboriginal and Rural Health Care, University of Western Australia, Perth, WA, Australia.
Heart, Lung & Circulation
|November 28, 2016
Summary
A simple electronic tool can identify patients at high risk of familial hypercholesterolaemia (FH) in general practice. This method helps increase FH detection and cardiovascular disease risk assessment.
Area of Science:
- Cardiology
- Genetics
- Public Health
Background:
- Familial hypercholesterolaemia (FH) is a genetic condition leading to premature cardiovascular disease.
- FH awareness is low, with only 10-15% of affected individuals identified.
- Electronic health records (EHR) offer a potential avenue for improving FH detection in primary care.
Purpose of the Study:
- To evaluate the effectiveness of a simple electronic extraction tool in increasing the detection of FH within general practice settings.
Main Methods:
- An electronic tool was utilized to screen general practice EHRs.
- The tool identified patients based on diagnostic criteria, demographic data, and cholesterol levels (total cholesterol and LDL-c).
- Data was analyzed from five general practices.
Main Results:
- Out of 157,290 patients, 0.7% had LDL-c > 5.0 mmol/L, indicating 1 in 146 patients at high risk.
- An additional 0.8% were identified as potentially at risk for FH.
- Notably, 43.7% of patients with elevated LDL-c were not on statin therapy, and only 0.013% had a recorded FH diagnosis.
Conclusions:
- A straightforward electronic screening method can effectively identify high-risk FH patients in general practice.
- Variability in clinical data entry within general practices was observed.
- This targeted screening approach facilitates clinical assessment for cardiovascular disease risk and improves FH identification in primary care, with approximately 20% of screened patients likely having probable FH.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
59
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
59
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
678
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
678

